RESUMO
A liquid chromatography-tandem mass spectrometric (LC-MS/MS) method was developed and validated for the determination of GDC-0152 in human plasma to support clinical development. The method consisted of a solid-phase extraction for sample preparation and LC-MS/MS analysis in the positive ion mode using TurboIonSpray(TM) for analysis. d(7) -GDC-0152 was used as the internal standard. A linear regression (weighted 1/concentration(2) ) was used to fit calibration curves over the concentration range of 0.02-10.0 ng/mL for GDC-0152. There were no endogenous interference components in the blank human plasma tested. The accuracy at the lower limit of quantitation was 99.3% with a precision (%CV) of 13.9%. For quality control samples at 0.0600, 2.00 and 8.00 ng/mL, the between-run %CV was ≤8.64. Between-run percentage accuracy ranged from 98.2 to 99.6%. GDC-0152 was stable in human plasma for 363 days at -20°C and for 659 days at -70°C storage. GDC-0152 was stable in human plasma at room temperature for up to 25 h and through three freeze-thaw cycles. In whole blood, GDC-0152 was stable for 12 h at 4°C and at ambient temperature. This validated LC-MS/MS method for determination of GDC-0152 was used to support clinical studies.
Assuntos
Cromatografia Líquida/métodos , Cicloexanos/sangue , Neoplasias/sangue , Pirróis/sangue , Extração em Fase Sólida/métodos , Espectrometria de Massas em Tandem/métodos , Cicloexanos/administração & dosagem , Cicloexanos/efeitos adversos , Cicloexanos/farmacocinética , Relação Dose-Resposta a Droga , Estabilidade de Medicamentos , Humanos , Modelos Lineares , Neoplasias/tratamento farmacológico , Pirróis/administração & dosagem , Pirróis/efeitos adversos , Pirróis/farmacocinética , Reprodutibilidade dos Testes , Sensibilidade e EspecificidadeRESUMO
A liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method was developed and validated for the determination of GDC-0834 and its amide hydrolysis metabolite (M1) in human plasma to support clinical development. The method consisted of semi-automated 96-well protein precipitation extraction for sample preparation and LC-MS/MS analysis in positive ion mode using TurboIonSpray® for analysis. D6-GDC-0834 and D6-M1 metabolite were used as internal standards. A linear regression (weighted 1/concentration(2) ) was used to fit calibration curves over the concentration range of 1 - 500 ng/mL for both GDC-0834 and M1 metabolite. The accuracy (percentage bias) at the lower limit of quantitation (LLOQ) was 5.20 and 0.100% for GDC-0834 and M1 metabolite, respectively. The precision (CV) for samples at the LLOQ was 3.13-8.84 and 5.20-8.93% for GDC-0834 and M1 metabolite, respectively. For quality control samples at 3, 200 and 400 ng/mL, the between-run CV was ≤ 7.38% for GDC-0834 and ≤ 8.20% for M1 metabolite. Between run percentage bias ranged from -2.76 to 6.98% for GDC-0834 and from -6.73 to 2.21% for M1 metabolite. GDC-0834 and M1 metabolite were stable in human plasma for 31 days at -20 and -70°C. This method was successfully applied to support a GDC-0834 human pharmacokinetic-based study.
Assuntos
Cromatografia Líquida/métodos , Pirimidinonas/sangue , Espectrometria de Massas em Tandem/métodos , Tiofenos/sangue , Precipitação Química , Método Duplo-Cego , Estabilidade de Medicamentos , Humanos , Modelos Lineares , Pirimidinonas/química , Pirimidinonas/metabolismo , Pirimidinonas/farmacocinética , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Tiofenos/química , Tiofenos/metabolismo , Tiofenos/farmacocinéticaRESUMO
Internal standard response is routinely monitored in regulated studies to accept or reject individual samples with outlier results due to potential sample processing or instrumentation errors, and processes are typically governed by standard operating procedures. However, acceptance or rejection of individual samples is not always sufficient. Internal standard response trends and substantial systemic differences between spiked and incurred samples using a method with an otherwise stable internal standard response should be investigated. Investigations may range from informal evaluations to detailed studies with formal investigation reports. Atypical internal standard response can be an indicator of systemic problems with a bioanalytical method and modification to allow for a relatively stable internal standard response across an analytical run may be essential.
Assuntos
Técnicas de Química Analítica/normas , Ensaios Enzimáticos/normas , Padrões de Referência , Projetos de Pesquisa , Estatística como AssuntoRESUMO
BACKGROUND: apixaban (BMS-562247) (Eliquis(®)) is a novel, orally active, selective, direct, reversible inhibitor of the coagulation factor Xa (FXa). A sensitive and reliable method was developed and validated for the measurement of apixaban (BMS-562247) and its major circulating metabolite (BMS-730823) in human citrated plasma for use in clinical testing. METHODOLOGY/RESULTS: A 0.100 ml portion of citrated plasma sample was extracted and analyzed by LC-MS/MS. Run times were approximately 3 min. The lower limit of quantification (LLOQ) was 1.00 ng/ml for BMS-562247 and 5.00 ng/ml for BMS-730823. Intra- and inter-assay precision values for replicate QC control samples were within ≤5.36% for both analytes (≤7.52% at the LLOQ). The accuracy for both analytes was within ±9.00%. CONCLUSION: The method was demonstrated to be sensitive, selective and robust, and was successfully used to support clinical studies.
Assuntos
Cromatografia Líquida de Alta Pressão/métodos , Pirazóis/sangue , Piridonas/sangue , Espectrometria de Massas em Tandem/métodos , Cromatografia Líquida de Alta Pressão/instrumentação , Inibidores do Fator Xa/sangue , HumanosRESUMO
A liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method was developed and applied for the determination of human Aß1-40 and Aß1-42 peptides in transgenic mouse plasma to support preclinical pharmacodynamics studies. The method consisted of micro-elution solid phase extraction for sample preparation and LC-MS/MS analysis in the negative ion mode using electrospray ionization for analysis. (15)N53-Aß1-40 and (15)N55-Aß1-42 peptides were used as internal standards. A quadratic regression (weighted 1/concentrations), with an equation y = ax(2) + bx + c, was used to fit calibration curves over the concentration range of 0.500-100 ng/mL for both Aß1-40 and Aß1-42 peptides. For quality control samples at 6.00, 40.0 and 80.0 ng/mL from the qualification experiment, the within-run accuracy ranged from -2.69 to 0.583 % with precision values ≤8.23 % for Aß1-40. Within-run accuracy ranged from -4.83 to 10.1 % with precision values ≤8.87 % for Aß1-42. Samples from a pharmacodynamics study using Tg2576 transgenic mice were analyzed by this qualified LC-MS/MS method and concentrations were compared to those generated by ELISA. The two methods were shown to be comparable for Aß1-40 quantification of samples from the Tg2576 amyloid precursor protein transgenic mouse model, but varied slightly for Aß1-42.
Assuntos
Peptídeos beta-Amiloides/sangue , Cromatografia Líquida , Fragmentos de Peptídeos/sangue , Microextração em Fase Sólida , Espectrometria de Massas em Tandem , Peptídeos beta-Amiloides/genética , Animais , Calibragem , Cromatografia Líquida/normas , Ensaio de Imunoadsorção Enzimática , Humanos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Fragmentos de Peptídeos/genética , Controle de Qualidade , Padrões de Referência , Reprodutibilidade dos Testes , Microextração em Fase Sólida/normas , Espectrometria de Massas por Ionização por Electrospray , Espectrometria de Massas em Tandem/normasRESUMO
A liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method was developed and validated for the determination of G-856 in human plasma to support clinical development. The method consisted of a solid phase extraction for sample preparation and LC-MS/MS analysis in the positive ion mode using TurboIonSpray for analysis. d8-G-856 was used as the internal standard. A linear regression (weighted 1/concentration²) was used to fit calibration curves over the concentration range of 5.00-2000 pg/mL for G-856. There were no significant endogenous interference components in the multiple lots of blank human plasma tested. The accuracy (%Acc) at the lower limit of quantitation (LLOQ) was 98.2% with a precision (%CV) of 5.38%. For quality control samples at 15.0, 800, and 1600 pg/mL, the inter-day %CV was ≤ 5.03%. Inter-day %Acc ranged from 96.9 to 99.3%. G-856 was stable in human plasma for 184 days at -20 °C and -70 °C storage. G-856 was stable in human plasma at room temperature for up to 16 h and through four freeze/thaw cycles. This validated LC-MS/MS method for determination of G-856 was used to support Phase 1 clinical studies.